Portable Raman Testing for THC: Why Saliva Success Does Not Validate a Urine Test

forensic toxicology working group members October 27, 2026 Forensic Toxicology

A portable Raman sensor can demonstrate THC detection without establishing a validated forensic test for every biological fluid. Research using diatomaceous surface-enhanced Raman spectroscopy shows why saliva and urine require separate evaluation.

How the method works

The study used a structured diatomaceous substrate to enhance Raman signals and a portable spectrometer to identify molecular spectral features. The investigators examined THC in complex fluids, including saliva collected shortly after cannabis consumption and urine preparations.

This was analytical method-development research involving laboratory samples and human-derived specimens. It did not assess driving performance, diagnose intoxication, or establish a blood THC threshold.

Urine introduced a different problem

Saliva samples collected within 15 minutes after consumption yielded THC-related spectral information. Urine contained interfering constituents, so the investigators incorporated thin-layer chromatography to separate material before Raman analysis. They examined spiked urine across a concentration range and also presented results from cannabis-user urine.

The extra separation step is substantive. A method demonstrated on a processed urine fraction cannot be described as requiring no preparation merely because the spectrometer is portable. Nor can a result in recently collected saliva establish how reliably the same device performs days after use.

Keep the analyte and instrument straight

The paper targets parent THC. That target should not be silently substituted for THC-COOH, the metabolite commonly addressed in urine cannabis testing. A validation claim must identify what chemical the assay actually measures.

The authors also discuss exceptionally low detection limits from earlier work using a different, confocal Raman arrangement. Those figures cannot be attributed to the portable configuration without its own supporting experiment. Instrument design and sample processing are part of the measurement.

What would support case-level use?

Relevant questions include reproducibility across donors, interference from other chemicals, performance near the decision threshold, and agreement with an independently validated reference method. Demonstration spectra do not by themselves provide population sensitivity or specificity.

The study supports further development of portable analysis. It does not establish that any positive spectrum proves impairment or that a negative result excludes exposure. Those conclusions require evidence about the precise matrix, analyte, operating conditions, and intended use.

For related context, see our discussion of why urine and blood drug results are not interchangeable.